

**Date: March 20, 2025**

To,  
The Listing Compliance Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G, BKC,  
Bandra (E), Mumbai - 400051

To,  
The Listing Compliance Department,  
**BSE Limited**  
Department of Corporate Services - Listing  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**Symbol: MEDICAMEQ**

**Scrip Code: 531146**

**Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice of Extra-Ordinary General Meeting.**

Dear Sir/Ma'am,

In continuation to our intimation dated March 03, 2025, we are hereby submitting the Corrigendum to the notice of the Extra Ordinary General Meeting (“EGM”) scheduled to be held on **Wednesday, March 26, 2025**, at 12:00 P.M. (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”).

A Corrigendum has been issued to inform the Shareholders of the Company, of the changes in the explanatory statement as set out for Item No. 1 & 2, contained in the EGM Notice. The same is enclosed herewith.

All other particulars and details as mentioned in the EGM Notice shall remain unchanged. The corrigendum shall be read in conjunction with the EGM Notice dated February 26, 2025, together with the explanatory statement. This corrigendum is also available on the Company’s website viz. [www.medicamen.com](http://www.medicamen.com), and on the website of the National Stock Exchange of India Limited (“NSE”) at [www.nseindia.com](http://www.nseindia.com) and BSE Limited (“BSE”) at [www.bseindia.com](http://www.bseindia.com) and on the website of Company's Registrar and Transfer Agent, MUFUG Intime India Private Limited (“MI IPL”) at [www.in.mpms.mufg.com](http://www.in.mpms.mufg.com).

You are requested to take the same on your record.

Thanking you,  
Yours faithfully,  
**For Medicamen Biotech Limited**

**Ms. Parul Choudhary**  
**Company Secretary & Compliance Officer**  
**Place: New Delhi**



**MEDICAMEN BIOTECH LIMITED**

**CIN: L74899DL1993PLC056594**

**Registered Office:** 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi – 110019, India

**Email:** [cs@medicamen.com](mailto:cs@medicamen.com) | **Website:** [www.medicamen.com](http://www.medicamen.com)

### **CORRIGENDUM TO THE NOTICE TO SHAREHOLDERS**

Medicamen Biotech Limited had issued a Notice dated February 26, 2025, for seeking approval of members for certain agenda items through the Extra-Ordinary General Meeting (“EGM”). The EGM Notice has already been circulated to all the Shareholders of the Company in due compliance with the provisions of the Companies Act, 2013 read with rules made thereunder.

The Company through this communication wishes to bring to the notice of the Shareholders, the following changes in the said EGM Notice:

#### **Changes to the Explanatory Statement to Item No. 1 and 2:**

Point No. I of the Explanatory Statement to the EGM Notice shall be substituted and read as under:

##### **Objects of the Preferential Issue:**

1. In the heading of object number b): the word “etc.” has been deleted.

The revised heading of object number b) is read as under:

##### ***b) Registration of dossiers:***

2. In the heading of object number d): the words “in some area of upgradation” has been deleted.

The revised heading of object number b) is read as under:

##### ***d) Capital expenditure of the existing facilities:***

3. The subpoint (3) of object number e) **Expansion of operations in Domestic Market** stating *Increased participation in domestic medical conferences to enhance brand recognition and engagement with healthcare professionals* has been deleted.

Accordingly, in the table mentioned under the heading **Utilization of Proceeds**, the said headings at point 2 and 4 shall be read as:

2. Registration of dossiers
4. Capital expenditure of the existing facilities.

All other particulars and details remain unchanged. The corrigendum shall be read in conjunction with the Notice of Extra-Ordinary General Meeting dated February 26, 2025, together with an explanatory statement. This corrigendum is also available on the Company's website at [www.medicamen.com](http://www.medicamen.com), and on the website of the National Stock Exchange of India Limited ("NSE") at [www.nseindia.com](http://www.nseindia.com) and BSE Limited at [www.bseindia.com](http://www.bseindia.com) ("BSE") and on the website of Company's Registrar and Transfer Agent, MUFGE Intime India Private Limited ("MIPL") at [www.in.mpms.mufg.com](http://www.in.mpms.mufg.com). The corrigendum shall also be sent electronically to all the registered shareholders of the Company.

Thanking you,

Yours faithfully,

**For Medicamen Biotech Limited**

**Ms. Parul Choudhary**

**Company Secretary & Compliance Officer**

**Place: New Delhi**

**Date: March 20, 2025**